Alligator Bioscience : to Participate in Upcoming Scientific and Industry Conferences in January and February 2023
January 01, 2023
Share
Lund, Sweden - Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that senior company representatives will participate in the following conferences during January and February 2023:
Redeye Fight Cancer Day 2023, January 19, Stockholm
Søren Bregenholt, Chief Executive Officer of Alligator Bioscience, will present the company, its latest developments, and upcoming catalysts to investors.
Aktiespararna "Aktiedagen i Lund", January 31, Lund
Søren Bregenholt, Chief Executive Officer of Alligator Bioscience, will present the company, its latest developments, and upcoming catalysts to investors.
ØU Life Science Investor Conference, February 22, Copenhagen, Denmark
Søren Bregenholt, Chief Executive Officer of Alligator Bioscience, will present the company, its latest developments, and upcoming catalysts to investors.
European Bispecific & Multispecific Antibody Congress, February 22 - 23, Amsterdam, Netherlands
Laura von Schantz, Vice President of Discovery at Alligator Bioscience, will give a presentation entitled "Reviewing the Landscape of Obligate MoAs for Bi-/Multispecifics to Prioritise and De-Risk Current and Future Efforts" at 2.30 pm CET on February 22.
Registration for the conference is open here.
The information was submitted for publication, through the agency of the contact persons set out below, at 8:00 a.m. CET on January 9, 2023.
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator's portfolio includes several promising drug candidates, with the CD40 agonist mitazalimab as its key asset. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its proprietary technology platform, Neo-X-Prime™, and novel drug candidates based on the RUBY™ bispecific platform with Orion Corporation. Out-licensed programs include AC101/HLX22, in Phase 2 development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc.
Alligator Bioscience's shares are listed on Nasdaq Stockholm (ATORX) and is headquartered in Lund, Sweden.
For more information, please visit alligatorbioscience.com.
Attachments
Alligator Bioscience to Participate in Upcoming Scientific and Industry Conferences in January and February 2023
Alligator Bioscience AB published this content on 02 January 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 January 2023 07:28:19 UTC.
Alligator Bioscience AB is a Sweden-based biotechnology Company that develops antibody-based drugs for cancer treatment. The Company specializes in the development of tumor-targeted immunotherapies, in particular agonist mono- and bispecific antibodies, and is active in the early stages of drug development, from concept to phase II clinical trials. Alligatorâs pipeline includes the two key assets mitazalimab, a CD40 agonist, and ATOR-1017, a 4-1BB agonist. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its technology platform, Neo-X-Prime, with MacroGenics Inc. and drug candidates based on the RUBY bispecific platform with Orion Corporation. Its licensed programs include AC101, in phase II development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc. The Company operates domestically.
ALLIGATOR BIOSCIENCE AB 
